Saftey & Long Term Outcomes of Tocilizumab (Anti-IL6R, TCZ) Therapy in Treatment of Chronic Antibody Mediated Rejection (CABMR) & Transplant Glomerulopathy (TG) in Highly-HLA Sensitized (HS) Patients (PTs)
AMERICAN JOURNAL OF TRANSPLANTATION（2017）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要